DCAT Week 2026: Key Pharma Manufacturing Announcements

DCAT Week 2026, New York draws together a pharmaceutical supply chain sector navigating familiar pressures: drug shortages, geopolitical risk, and the ongoing demand for domestic manufacturing resilience.1-3 Three announcements timed to coincide with the event reflect distinct strategies for responding to those pressures.

Is the Case for Domestic Finished Dose Manufacturing Getting Stronger?

LGM Pharma is committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado, bringing its total investment across both sites to $15 million.1 The announcement builds on a $6 million expansion at the Texas facility completed in 2025 and is aimed at expanding commercial capacity, extending research and development capabilities, and meeting sustained demand for U.S.-based drug product manufacturing.

In Texas, $4 million will go toward expanding commercial-scale manufacturing suites for suppositories, driven in part by increasing demand in women's health.1 The site will also gain expanded development capabilities for formulations including solutions, suspensions, and semi-solids. In Colorado Springs, a $5 million investment will increase commercial manufacturing capacity for niche oral solid dose products, with a particular focus on orally disintegrating tablets. This format is in growing demand as the domestic oral solid dose market continues to expand.

"These multi-site investments totaling $15 million reflect our continued commitment to strengthening pharmaceutical supply chains in the United States," said Prasad Raje, chief executive officer, LGM Pharma, in a press release.1

The company is building finished dose capacity at the downstream end of the supply chain while pairing it with upstream active pharmaceutical ingredient sourcing through a network of more than 220 pre-qualified manufacturers.1 "Today's pharma companies need partners that are both resilient and integrated across the full product lifecycle," Raje added.1 "By reinforcing domestic drug product manufacturing at the downstream end of the supply chain, closer to end markets, and leveraging our global API sourcing capabilities upstream, we create a balanced end-to-end model."

Importantly for companies with active programs, both facilities will remain fully operational throughout construction.1 "Rather than overextending in a single phase, we are executing these enhancements incrementally to expand capabilities and capacity while ensuring operational continuity," said Hamilton Lenox, chief commercial officer, LGM Pharma, in the press release.1

How Far Can a Single Molecular Class Extend Across Markets?

ICE Pharma, a global leader in Ursodeoxycholic Acid, is using DCAT Week to announce a deliberate move beyond the traditional active pharmaceutical ingredient supplier model.2 The company is repositioning its bile acid platform to serve finished dosage, nutraceutical, and specialty excipient markets.

The strategy rests on three areas.2 First is a focus delivering finished dosage forms of Ursodeoxycholic Acid to complement its established ingredient business. As well, advancing nutraceutical solutions targeting gut health and metabolic balance. They also plan on expanding bile acid derivatives into functional excipients designed to enhance formulation performance.

"ICE Pharma is evolving beyond the traditional API supplier model by exploring and developing new applications of bile acids, with the goal of opening new market opportunities," said Agostino Barazza, chief executive officer, ICE Pharma, in a press release.2

The move reflects a broader trend of ingredient suppliers seeking to capture more value across the product chain.2 For pharmaceutical developers working with bile acid chemistry, the shift may offer more integrated options for sourcing and formulation support. "Bile acids are an underutilized but highly versatile molecular class," added Dr. Roger Viney, chief commercial officer, ICE Pharma, in a press release.2 "Our strategy is to leverage our chemistry, regulatory expertise and manufacturing infrastructure to provide integrated solutions — not just ingredients — to pharmaceutical and healthcare partners."

What Innovations Are Being Shown for Development Pipelines?

ESTEVE CDMO is announcing an expansion of its spray drying infrastructure at its facility in Celrà, in Spain's Girona region, alongside the launch of a new brand identity.3 The expansion adds a 3,000-square-meter production unit to accommodate new spray drying equipment within purpose-built high-potency containment suites.

According to Esteve, their GEA Pharma spray dryer is scheduled to be operational in the first quarter of 2027, followed by a second unit expected to come online later that year.3 The new building also includes infrastructure to accommodate a commercial-scale third dryer, with further expansion beyond that planned. The company expects to add up to 15 staff once the first two units are in operation.

"As our work in Girona progresses, it is important that we remain aligned with the needs of our partners, and adding spray drying capabilities can help solve problems they face with the characteristics of development pipelines, such as stability, poor solubility, potency, and scalability," said Joan Petit, President, ESTEVE CDMO, in a press release.3

Taken together, these announcements reflect a sector investing in specificity, whether that means deeper domestic infrastructure, extended chemistry platforms, or targeted capabilities for complex molecules.1-3 DCAT Week 2026 continues to offer concrete signals about where the industry is being built upon.

References

1. LGM Pharma. LGM Pharma expands U.S. manufacturing, bringing total investment to 15 million dollars across Texas and Colorado sites [press release]. Boca Raton, FL; March 19, 2026. https://www.businesswire.com/news/home/20260319065768/en/LGM-Pharma-Expands-U.S.-Manufacturing-Bringing-Total-Investment-to-%2415M-Across-Texas-and-Colorado-Sites
2. ICE Pharma. ICE Pharma expands beyond APIs to capture new bile acid markets [press release]. Milan, Italy. ICE Pharma; 2026.
3. ​ESTEVE CDMO. ESTEVE CDMO plans additional spray dryers and containment in Girona, Spain, and launches new brand [press release]. Celrà (Girona), Spain; March 19, 2026. https://www.esteve.com/global/media/news/esteve-cdmo-plans-additional-spray-dryers-and-containment-in-girona-spain-and-launches-new-brand